Price movement over the last 24 hours
Abeona Therapeutics Inc vs United States Oil ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while United States Oil ETF trades at $111.7. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | USO | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $152.96 |
52-Week Low | $4.17 | $66.17 |
Enterprise Value | $228.22M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
USO (United States Oil Fund) trades at $104.35, showing modest daily gains of 0.36% amid heightened geopolitical tensions in the Middle East. Technical indicators signal a bearish trend with moving averages showing strong sell signals, though oscillators remain neutral. The fund's price action reflects direct exposure to crude oil volatility, with recent U.S. military strikes against Iran and attacks in the Strait of Hormuz driving supply disruption fears and price increases.
The outlook remains heavily dependent on geopolitical developments and oil supply dynamics. While recent Middle East tensions provide upward price pressure, risks include potential supply increases from Gulf producers and weak demand signals that could limit sustained recovery. The fund offers direct commodity exposure but faces contango risks and tracking error inherent to futures-based ETFs.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →